XML 84 R68.htm IDEA: XBRL DOCUMENT
v3.25.1

ORGANIZATION AND BASIS OF PRESENTATION - Additional information (Details) ¥ in Thousands, $ in Thousands |  |  |  |  |  |  |  | 1 Months Ended | 12 Months Ended |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 01, 2020 | Apr. 07, 2020 CNY (¥) shares | Nov. 13, 2019 CNY (¥) | Aug. 23, 2019 CNY (¥) | Jul. 22, 2019 CNY (¥) | Jul. 10, 2018 CNY (¥) shares | Mar. 26, 2018 shares | Jun. 30, 2023 CNY (¥) | Jun. 30, 2023 USD ($) | Mar. 31, 2022 | Apr. 30, 2021 CNY (¥) shares | Jun. 30, 2018 CNY (¥) | Nov. 30, 2017 CNY (¥) | Nov. 30, 2016 CNY (¥) | Jan. 31, 2016 CNY (¥) | Dec. 31, 2024 CNY (¥) | Dec. 31, 2024 USD ($) | Dec. 31, 2023 CNY (¥) | Dec. 31, 2022 CNY (¥) | Dec. 31, 2020 | Dec. 31, 2017 CNY (¥) | Dec. 31, 2024 USD ($) | Apr. 30, 2022 | Dec. 31, 2021 CNY (¥) | Nov. 19, 2020 | Dec. 31, 2019 CNY (¥) | Dec. 31, 2019 USD ($) | Nov. 18, 2019 CNY (¥)
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity method investments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ¥ 428,842 |  | ¥ 324,163 |  |  |  | $ 58,751 |  |  |  |  |  |
Contingently redeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,617,749 |  | 1,746,987 | ¥ 2,015,657 |  |  | 221,633 |  | ¥ (937,061) |  |  |  |
Common unit value authorized |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ¥ 1,009,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingently redeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,898,139 |  | 3,868,932 | ¥ 3,879,623 |  |  | $ 534,044 |  | 433,055 |  |  |  |
Contingently redeemable noncontrolling Interest |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingently redeemable noncontrolling interests |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ¥ 0 |  | ¥ 0 |  |  |  |  |  | ¥ 3,680,782 |  |  |  |
Shanghai Xinhe Enterprise Management Center (Limited Partnership) ("Shanghai Xinhe") |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity interest in equity method investment |  |  |  |  |  |  |  |  |  | 99.99% |  |  |  |  |  | 72.73% |  | 72.23% |  |  |  | 72.73% |  |  |  |  |  |
Percentage of shares as consideration |  |  |  |  |  |  |  |  |  | 2.05% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Guofu Huimei Investment Management Limited Partnership |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity method investments |  |  |  |  |  |  |  |  |  |  |  | ¥ 746,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ZR Group |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of ownership in equity interest to be repurchased |  |  |  |  |  |  |  |  |  |  |  |  |  | 75.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration to be made on acquisition of equity interest |  |  |  |  |  |  |  |  |  |  |  |  |  | ¥ 521,396 |  |  |  |  |  |  |  |  |  |  |  |  |  |
ZR Group | ZR ConcordHealthcare Investment Fund SP ("SP") |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Creditor's rights settled for acquisition of equity interest |  |  |  |  |  |  |  |  |  |  |  |  |  | 166,299 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business combination, consideration transferred |  |  |  |  |  |  |  |  |  |  |  |  |  | ¥ 7,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |
ZR Guofu |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of equity interest withdrawn |  |  | 77.18% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration |  |  | ¥ 421,730 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Period of equity interest repurchased |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Creditor's rights settled for acquisition of equity interest |  |  |  |  |  |  |  |  |  |  |  |  | ¥ 97,106 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration for repurchase of equity interest |  |  |  |  |  |  |  |  |  |  |  |  |  | ¥ 521,396 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual premium percentage to be paid |  |  |  |  |  |  |  |  |  |  |  |  |  | 15.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Partners' capital account, contributions |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ¥ 746,001 |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of interest in partnership |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 73.93% |  |  |  |  |  |  |  |  |  |  |  |  |
ZR Guofu | ZR ConcordHealthcare Investment Fund SP ("SP") |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration to be made on acquisition of equity interest |  |  |  |  |  |  |  |  |  |  |  |  |  | ¥ 521,396 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shanghai Rongchi Medical Management Limited |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common unit value authorized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ¥ 695,305 |  |  |  |  |  |  |
The Group |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Partners' capital account, contributions |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ¥ 262,999 |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of interest in partnership |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 26.07% |  |  |  |  |  |  |  |  |  |  |  |  |
Shanghai Meizhong Jiahe Imaging Diagnostic Center Co., Ltd. ("SH MZJH") |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Capital contributed |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ¥ 34,540 |  |
Shanghai Meizhong Jiahe Imaging Diagnostic Center Co., Ltd. ("SH MZJH") | ZR ConcordHealthcare Investment Fund SP ("SP") |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Creditor's rights settled for acquisition of equity interest |  |  |  | ¥ 82,100 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Beijing Century Friendship Science and Technology Development Co., Ltd. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of equity interest sold |  |  |  |  |  |  |  |  |  |  |  | 100 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business combination, consideration transferred |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 388,500 |  |  |  |  |  |  |
Shanghai Meizhongjiahe ProMed Cancer Centers Co., Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of equity interest sold |  |  |  |  |  |  |  |  |  |  |  | 90 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business combination, consideration transferred |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 182,100 |  |  |  |  |  |  |
Tianjin Jiatai Entity Management limited Partnership |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business combination, consideration transferred |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ¥ 106,500 |  |  |  |  |  |  |
Shanghai Meizhong Jiahe Imaging Diagnostic Center Co., Ltd. ("SH MZJH") |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of equity interest sold |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 78.34 |  | 56.77 |  |  |  | 78.34 |  |  |  |  |  |
Capital contributed | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,105 |
Business combination, consideration transferred |  |  |  |  | ¥ 27,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Concord Healthcare Group Co., Ltd. ("Concord Healthcare") (formerly known as Meizhong Jiahe Medical Technology Development Group Co., Ltd.) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of interest held after disposal | 2.12% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Medstar (Shanghai) Enterprise Management Company Limited ("Shanghai Medstar") |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of equity interests acquired |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 98.19% |  |  |  |  |  | 98.19% |  |  |  |  |  |
Beijing Proton Medical Center Co., Ltd ("BPMC") |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of equity interests acquired |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 54.01% |  |  |  |  |  | 54.01% |  |  |  |  |  |
Percentage of equity interest sold |  |  |  |  |  |  |  |  |  |  |  | 80 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tianjin Jiatai Group |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of equity interest sold |  |  |  |  | 90 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Redeemable noncontrolling interest, equity, common, carrying amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ¥ 434,216
Tianjin Concord Medical Technology Limited ("Tianjin Concord Medical") |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of equity interests acquired |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 98.19% |  |  |  |  |  | 98.19% |  |  |  |  |  |
Concord Healthcare Group Co., Ltd. ("Concord Healthcare") (formerly known as Meizhong Jiahe Medical Technology Development Group Co., Ltd.) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of equity interests acquired |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 39.77% |  |  | 43.90% |  |  | 39.77% |  | 46.56% |  |  |  |
Noncontrolling interest, ownership percentage by noncontrolling owners | 2.36% |  |  |  |  |  |  | 5.28% | 5.28% |  | 5.28% |  |  |  |  |  |  |  |  |  |  |  | 5.28% |  |  |  |  |
Percentage of interest held after disposal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 49.44% |  |  |  |  |  |  |  |
Guangzhou Concord Medical Cancer Hospital Co Ltd | ZR Guofu |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of shares acquire for business |  |  |  |  |  |  |  |  |  |  |  |  |  | 70.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
PTC Houston Management | ZR Guofu |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of shares acquire for business |  |  |  |  |  |  |  |  |  |  |  |  |  | 59.51% |  |  |  |  |  |  |  |  |  |  |  |  |  |
CCM Hospital Business | ZR Guofu |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of shares acquire for business |  |  |  |  |  |  |  |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Concord Healthcare Group Co., Ltd. ("Concord Healthcare") (formerly known as Meizhong Jiahe Medical Technology Development Group Co., Ltd.) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of equity interest sold |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.08 |  | 50.23 |  |  |  | 50.08 |  |  |  |  |  |
Business acquisition, equity interest issued or issuable, number of shares | shares |  | 38,888,888 |  |  |  | 40,000,000 | 60,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Concord Healthcare Group Co., Ltd. ("Concord Healthcare") (formerly known as Meizhong Jiahe Medical Technology Development Group Co., Ltd.) | CITIC Industrial |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business combination, consideration transferred |  | ¥ 700,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Concord Healthcare Group Co., Ltd. ("Concord Healthcare") (formerly known as Meizhong Jiahe Medical Technology Development Group Co., Ltd.) | Beijing Century Friendship Science and Technology Development Co., Ltd. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of interest in partnership |  |  |  |  |  |  |  |  |  |  |  | 78.31% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Concord Healthcare Group Co., Ltd. ("Concord Healthcare") (formerly known as Meizhong Jiahe Medical Technology Development Group Co., Ltd.) | Shanghai Meizhongjiahe ProMed Cancer Centers Co., Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business combination, consideration transferred |  |  |  |  |  |  |  |  |  |  |  | ¥ 182,100 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Concord Healthcare Group Co., Ltd. ("Concord Healthcare") (formerly known as Meizhong Jiahe Medical Technology Development Group Co., Ltd.) | CCIC Capital and Other Investor |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business combination, consideration transferred |  |  |  |  |  | ¥ 1,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Concord Healthcare Group Co., Ltd. ("Concord Healthcare") (formerly known as Meizhong Jiahe Medical Technology Development Group Co., Ltd.) | Beijing Proton Medical Center Co., Ltd ("BPMC") |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of equity interests acquired |  |  |  |  |  |  |  |  |  |  |  | 55.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business combination, consideration transferred |  |  |  |  |  |  |  |  |  |  |  | ¥ 388,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Concord Healthcare Group Co., Ltd. ("Concord Healthcare") (formerly known as Meizhong Jiahe Medical Technology Development Group Co., Ltd.) | Shanghai Meizhong Jiahe Cancer Center Co Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of equity interests acquired |  |  |  |  |  |  |  |  |  |  |  | 54.80% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Beijing Century Friendship Science and Technology Development Co., Ltd. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Voting interest acquired |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 78.31% |  |  |  |  |  |  |
Beijing Proton Medical Center Co., Ltd ("BPMC") |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Voting interest acquired |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 55.00% |  |  |  |  |  |  |
Shanghai Meizhongjiahe ProMed Cancer Centers Co., Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Voting interest acquired |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 54.80% |  |  |  |  |  |  |
Tianjin Jiatai Entity Management limited Partnership |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Voting interest acquired |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 28.77% |  |  |  |  |  |  |
Investors 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business combination, consideration transferred |  |  |  |  |  |  |  |  |  |  | ¥ 400,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business acquisition, equity interest issued or issuable, number of shares | shares |  |  |  |  |  |  |  |  |  |  | 18,805,826 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
CHS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage interest shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 90.00% |  |  |
Percentage of remaining interest disposed subsequently |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10.00% |  |  |
Business combination, consideration transferred |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ¥ 27,664 | $ 3,790 |  |  |  |  |  |  |  |  |  |  |
Concord Healthcare |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ORGANIZATION AND BASIS OF PRESENTATION |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage interest shares |  |  |  |  |  |  |  | 4.17% | 4.17% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of interest held after disposal |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 42.09% | 43.90% |  |  |  |  |  |  |  |  |
Business combination, consideration transferred |  |  |  |  |  |  |  | ¥ 300,000 | $ 42,254 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition It represents the percentage of annual premium to be paid. + References No definition available. + Details
Name: | ccm_AnnualPremiumPercentageToBePaid
Namespace Prefix: | ccm_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of capital contributed. + References No definition available. + Details
Name: | ccm_CapitalContributed
Namespace Prefix: | ccm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition It represents the common unit authorised. + References No definition available. + Details
Name: | ccm_CommonUnitValueAuthorized
Namespace Prefix: | ccm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of consideration which will be payable on acquisition of equity interest. + References No definition available. + Details
Name: | ccm_ConsiderationToBeMadeOnAcquisitionOfEquityInterest
Namespace Prefix: | ccm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of creditor's right settled for acquisition of equity interest. + References No definition available. + Details
Name: | ccm_CreditorSRightsSettledForAcquisitionOfEquityInterest
Namespace Prefix: | ccm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The period at the end of which equity interest is required to be contractually repurchased. + References No definition available. + Details
Name: | ccm_EquityInterestRepurchasePeriodInForce
Namespace Prefix: | ccm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents the percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References No definition available. + Details
Name: | ccm_EquityMethodInvestmentOwnershipPercentage1
Namespace Prefix: | ccm_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of consideration to be made for repurchase of equity interest. + References No definition available. + Details
Name: | ccm_PaymentsToRepurchaseEquityInterest
Namespace Prefix: | ccm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition It represents the percentage of equity interest withdrawn. + References No definition available. + Details
Name: | ccm_PercentageOfEquityInterestWithdrawn
Namespace Prefix: | ccm_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents the percentage of interest in partnership. + References No definition available. + Details
Name: | ccm_PercentageOfInterestInPartnership
Namespace Prefix: | ccm_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition It represents the percentage of ownership in equity interest to be repurchased. + References No definition available. + Details
Name: | ccm_PercentageOfOwnershipInEquityInterestToBeRepurchased
Namespace Prefix: | ccm_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The value represents percentage of share acquire for business + References No definition available. + Details
Name: | ccm_PercentageOfSharesAcquireForBusiness
Namespace Prefix: | ccm_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of shares issued as consideration for equity method investments. + References No definition available. + Details
Name: | ccm_PercentageOfSharesIssuedAsConsiderationForEquityMethodInvestments
Namespace Prefix: | ccm_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details
Name: | us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of voting equity interests acquired in a business combination achieved in stages, including equity interests in the acquiree held by the acquirer immediately before the acquisition date and acquired at the acquisition date. + References No definition available. + Details
Name: | us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination. + References No definition available. + Details
Name: | us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_MinorityInterestLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. + References No definition available. + Details
Name: | us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The parent entity's interest in net assets of the subsidiary, expressed as a percentage. + References No definition available. + Details
Name: | us-gaap_MinorityInterestOwnershipPercentageByParent
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total contributions made by each class of partners (i.e., general, limited and preferred partners). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 4.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_PartnersCapitalAccountContributions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of common shares (regardless of class), limited partnership units (regardless of class), non-preferential membership interests, or any other form of common equity regardless of investee entity legal form. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Subparagraph (12)(c) -Section S99 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Subparagraph (16)(c) -Paragraph 3A -Section S99 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 480 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3A -Subparagraph (15) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 480 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3A -Subparagraph (14) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A + Details
Name: | us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash received on stock transaction after deduction of issuance costs. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8 Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4 Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1 Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7 Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5 Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1 Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17 Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3 Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3 Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2 Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15 Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16 Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I Reference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details
Name: | us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=ccm_ContingentlyRedeemableNoncontrollingInterestMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ccm_ShanghaiXinheEnterpriseManagementCenterLimitedPartnershipMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=ccm_GuofuHuimeiInvestmentManagementLimitedPartnershipMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=ccm_ZrGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=ccm_ZhongrongInternationGrowthFundSpczrConcordhealthcareInvestmentFundSpSpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=ccm_ZrGuofuMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=ccm_ShanghaiRongchiMedicalManagementLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=ccm_TheGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ccm_ShanghaiMeizhongJiaheImagingDiagnosticCenterCoLtdshMzjhMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=ccm_BeijingCenturyFriendshipScienceAndTechnologyDevelopmentCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=ccm_ShanghaiMeizhongjiahePromedCancerCentersCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=ccm_TianjinJiataiEntityManagementLimitedPartnershipMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=ccm_ShanghaiMeizhongJiaheImagingDiagnosticCenterCoLtdshMzjhMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=ccm_ConcordHealthcareGroupCo.Ltd.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=ccm_MedstarShanghaiLeasingCoLtdShanghaiMedstarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=ccm_BeijingProtonMedicalCenterCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=ccm_TianjinJiataiGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=ccm_TianjinConcordMedicalTechnologyLimitedtianjinConcordMedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=ccm_ConcordHealthcareGroupCo.Ltd.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ccm_GuangzhouConcordMedicalCancerHospitalCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ccm_PtcHoustonManagementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ccm_CcmHospitalBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ccm_ConcordHealthcareGroupCo.Ltd.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=ccm_CiticIndustrialInvestmentGroupLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=ccm_CcicCapitalAndOtherInvestorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=ccm_ShanghaiMeizhongJiaheCancerCenterCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ccm_BeijingCenturyFriendshipScienceAndTechnologyDevelopmentCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ccm_BeijingProtonMedicalCenterCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ccm_ShanghaiMeizhongjiahePromedCancerCentersCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ccm_TianjinJiataiEntityManagementLimitedPartnershipMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ccm_Investors2021Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ccm_ConcordHealthcareSingaporePteLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ccm_ConcordHealthcareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |